DKY709 + PDR001 for Cancer
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drugs DKY709 and PDR001 for cancer treatment?
The research on immune checkpoint inhibitors, like PDR001, shows that they can be effective in treating certain types of cancer, such as colorectal cancer with specific genetic features, by helping the immune system attack cancer cells. Additionally, studies on similar drugs targeting the same pathways suggest potential benefits in cancer treatment.12345
What safety data exists for DKY709 + PDR001 in cancer treatment?
What makes the DKY709 + PDR001 drug unique for cancer treatment?
The DKY709 + PDR001 drug combination is unique because it targets the PD-1/PD-L1 pathway, which is involved in immune suppression by cancer cells. This approach can potentially enhance the immune system's ability to fight cancer, offering a novel strategy compared to traditional treatments that do not focus on immune checkpoint blockade.1112131415
What is the purpose of this trial?
This trial tests DKY709 alone and with PDR001 in patients with certain cancers who didn't respond to previous treatments. It aims to see if these drugs can improve the immune system's ability to fight cancer.
Eligibility Criteria
Adults (≥18 years) with advanced cancers like NSCLC, melanoma, NPC, mssCRC, or TNBC who have progressed after standard therapy or are intolerant to it. Participants must have measurable disease and be willing to undergo tumor biopsies. Excluded are those with significant heart issues, severe allergies to study drugs' ingredients, certain abnormal lab values, symptomatic CNS metastases or recent cardiac events.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001
Dose Expansion
Further assess safety, tolerability, PK/PD, and anti-tumor activity at the MTD/RD
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DKY709
- PDR001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD